Traders, pressed to find some action, are chasing certain things to a ridiculous extent.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits
These five stocks trading for less than $10 a share are within range of triggering breakout trades.
Biotech stocks large and small were plummeting as 2016's painful start began to turn torturous.
TheStreet highlights 3 stocks pushing the Drugs industry lower today.
Shares of GenVec (GNVC) were up 12.83% to $2.99 in aftermarket trading Thursday.
Keep an eye on these under-$10 biotech stocks.
GenVec's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of investors who purchased GenVec, Inc.
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of investors who purchased GenVec, Inc.
The law firm of Brower Piven, A Professional Corporation, is investigating potential securities fraud claims against GenVec, Inc.
The blowup of GenVec's drug for pancreatic cancer in a phase III study reduces fair value to around 30 cents a share.
Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.
Here are ten biotech and drug companies facing upcoming, potentially stock-moving events.
March's list of important, potentially stock-moving biotech events
In a bonus edition of Mailbag, our biotech columnist answers readers' questions about healthcare stocks and the FDA.
Several stocks trading near or under $5 were poised to move on above-average volume during Friday's trading session.
News of clinical trial results can make or break a drug. Here are ten companies expected to announce important results in coming months.
Columnist Adam Feuerstein reports on fan mail, hate mail and readers' queries about Keryx and other biotech stocks.
Several stocks trading near $5 were moving on above-average volume during Wednesday's session.
Offering comes right before data read-out from a crucial cancer drug trial.
Senior columnist Adam Feuerstein responds to readers' biotech stock questions -- and lets Adventrx Pharmaceuticals' CEO sound off in response to a couple recent columns.
Introducing the Biotech Stock Mailbag Readers' Portfolio, which highlights stocks picked by readers and regularly-updated analysis from columnist Adam Feuerstein.
Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.
Several stocks trading near $5 were poised to move on above-average volume during Thursday's session.
A rundown of what to expect at next week's San Francisco biotech conference.
Several stocks trading near $5 were moving on above-average volume during Monday's session.
The fall in Cardium shares might be related, at least partially, to what looks like so-so results from a phase IIb study announced on Oct. 14.
